Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204399 | 1.00 | ADRB2 (0.52) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1204729 | 0.91 | ADRB2 (0.51) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1204726 | 0.91 | ADRB2 (0.51) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1205549 | 0.89 | ADRB2 (0.59) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1205548 | 0.89 | ADRB2 (0.59) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1204763 | 0.88 | ADRB2 (0.63) | ADRB2ADRB1ADRA1D | |
| SCHEMBL1204760 | 0.88 | ADRB2 (0.63) | ADRB2ADRB1ADRA1D | |
| SCHEMBL1205667 | 0.88 | ADRB2 (0.56) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1205668 | 0.88 | ADRB2 (0.56) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL1204705 | 0.87 | ADRB2 (0.57) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-02-03 | — | — | US | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| EP-2096105-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor | Laboratorios Almirall, S.A. (ES) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.